Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNMOSTAR observational study of mosunetuzumab plus polatuzumab vedotin in relapsed or refractory aggressive non-Hodgkin lymphoma
jRCT1071260043Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of mosunetuzumab and polatuzumab vedotin in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 1 more, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: overall survival. Started Jun 2026; status: recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT1071260043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071260043.